Empliciti 400 mg powder for concentrate for solution for infusion. clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
This study looks at how long people with multiple myeloma, a type of blood cancer, continue taking elotuzumab or other treatments after being in an earlier study. It also checks for any side effects experienced.
For: Multiple MyelomaRomania - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.
For: multiple myelomaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.
For: Relapsed and/or Refractory Multiple MyelomaGermany · Italy · Sweden